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MetAP substrates and their physiological roles have remained elusive. In this issue of Chemistry &
Biology, Hu and colleagues [1] employ a small molecule approach to study the impact of MetAP
inhibition on the molecular regulation and cellular functions of the proto-oncogene c-Src.All mammalian cells express two cata-
lytically active isoforms of a class of
metallopeptidases, methionine amino-
peptidases type 1 (MetAP-1) and type
2 (MetAP-2). These enzymes cotrans-
lationally remove the initiator methio-
nine from nascent polypeptide chains,
the most common protein modifica-
tion that is involved in the regulation
of important cellular processes, in-
cluding protein targeting to specific
cellular compartments and cell prolif-
eration. Not surprisingly, studies of
a wide range of biological systems in
which the MetAPs were manipulated,
using chemical, genetic, or combined
approaches have yielded results that
have reinforced the notion of an essen-
tial role for these enzymes, ultimately
for cell growth and survival [2–4]. These
studies have also shown a significant
degree of conserved functional re-
dundancy, yet distinct substrate spec-
ificities between MetAP-1 and MetAP-
2 [5, 6]. Contradicting the concept
of functional redundancy shared by
these two enzymes are observations
that the proliferation of endothelial
cells and a few other cell types is
exquisitely sensitive to inhibition of
either MetAP isoform [5, 7, 8]. More-
over, the recent analysis of conditional
MetAP-2 knockout mice has revealed
an essential role for this enzyme in
vertebrate development, further high-
lighting the critical role of individual
MetAPs in the regulation of cellular
processes [4].
These dramatic changes that are set
in motion as a consequence of MetAP
inhibition demand explanations that
extend beyond the phenotypic de-
scription of affected cells. Specifically,
the molecular targets and the underly-
ing downstream effector mecha-
nism(s) involved in the control of these732 Chemistry & Biology 14, July 2007 ª2cellular responses need to be identi-
fied. However, the identification of
physiological substrates processed
by MetAPs and the decoding of their
links to specific cellular responses
have remained largely elusive and con-
stitutes the ‘‘black box’’ of MetAP biol-
ogy. This ‘‘black box’’ holds the key to
a number of fundamental questions.
The answers to those questions could
trigger a new interest and stepped-up
efforts in basic MetAP research and
importantly, could have significant
therapeutic implications for thediscov-
ery of novel clinical targets.
In this issue of Chemistry & Biology,
Hu and colleagues [1] take an impor-
tant first step in this direction. The au-
thors employ a clever combination of
in vitro and in vivo experiments to
demonstrate conclusively that the
proto-oncogene c-Src is a common
substrate of MetAP-1 and MetAP-2
and that the simultaneous inhibition
of both MetAPs provokes serious
‘‘predicted’’ consequences. An essen-
tial prerequisite for c-Src translocation
to the plasma membrane and for its
activity as a tyrosine kinase is its
myristoylation at the penultimate
glycine residue by the enzyme N-
myristoyltransferase (Figure 1) [9]. This
cotranslational modification in turn is
dependent on the prior removal of the
N-terminal methionine from c-Src by
MetAP peptidase activity. Here, the
authors advance a hypothesis that is
built on prior findings from an inves-
tigation of the global pattern of N-
myristoylated proteins in endothelial
cells following the selective inhibition
of MetAP-2 in these cells by TNP-
470, a small-molecule MetAP-2 inhibi-
tor of the fumagillin class [5]. With the
single exception of endothelial nitric
oxide synthase (eNOS), no differences007 Elsevier Ltd All rights reservedin N-myristoylation were observed,
suggesting that MetAP-1 activity com-
pensated for the loss of MetAP-2
activity in these cells. Nevertheless,
differentially myristoylated eNOS of-
fered a first view into the world of myr-
istoylated proteins directly affected by
MetAP activity. Moreover, these re-
sults suggested that more targeted
and innovative approaches would be
necessary to gain further insights into
the myristoylation of physiologically
relevant MetAP substrates and their
link to cellular processes. Such strat-
egy is successfully implemented in
Hu’s current study.
The authors first examined c-Src
myristoylation levels following the inhi-
bition of eitherMetAP-1 orMetAP-2, or
after simultaneous inhibition of both
enzymes. In these experiments, sev-
eral chemically and mechanistically
diverse MetAP inhibitors were used,
including bengamide A, a nonspecific,
reversible inhibitor of MetAP-1 and
MetAP-2, IV-43, a reversible MetAP-1
inhibitor, and TNP-470, a selective,
covalent MetAP-2 inhibitor. Benga-
mide A treatment of HEK293 cells en-
gineered to transiently overexpress
a tagged version of c-Src resulted in
the retention of its initiator methionine,
while neither IV-43 nor TNP-470 treat-
ment protected c-Src from N-terminal
processing by MetAP peptidase activ-
ity. These results confirmed the exis-
tence of functional redundancy of
MetAP-1 and MetAP-2 and that c-Src
is a common in vivo substrate of these
enzymes. The authors then correctly
predicted that the retention of the c-
Src initiator methionine in bengamide
A treated cells would result in a de-
crease of N-terminal c-Src myristoyla-
tion and conversely, that treatment
with either IV-43 or TNP-470 would
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(A) In NIH-3T3 cells which overexpress wild-type c-Src, c-Src detected by immunostaining is associated with the plasma membrane (open arrows)
and perinuclear structures (arrowheads). (B) In contrast, the overexpression of a myristoylation-deficient c-Src mutant shows nuclear localization
(black arrows) and diffuse cytoplasmic distribution (arrowheads). Reproduced with permission of the Company of Biologists.only moderately affect this cotransla-
tional modification. Hu et al. [1] went
on to demonstrate that the altered
myristoylation of c-Src in bengamide
A treated cells significantly impacted
the subcellular localization of the ki-
nase. The association of c-Src with
the plasma membrane is a critical
step for the ability of the c-Src to initi-
ate signaling pathways upon activa-
tion by a broad spectrum of mem-
brane-bound receptors. Bengamide
A treatment of HeLa cells resulted in
a marked redistribution of c-Src from
the plasma membrane to the cytosolic
compartment and the nucleus, a phe-
nomenon not observed in IV-43 or
TNP-470 treated cells.
The dramatic changes in the cellu-
lar localization of c-Src observed after
bengamide A treatment prompted
the authors to investigate whether
this redistribution would also affect
its tyrosine kinase activity. Tyrosine
kinase activity of plasma membrane-
associated c-Src is dependent on se-
quential dephosphorylation (tyrosine-
530) by a protein tyrosine phosphatase
and c-Src autophosphorylation of ty-
rosine residue 419. The finding that
c-Src immunoprecipitated from ben-
gamide A treated cells had signifi-
cantly lower tyrosine kinase activity
than that from control cells, combined
with results that treatment with either
IV-53 or TNP-470 had no detectable
effects, further supported the notion
that c-Src is a common substrate of
MetAP-1 and MetAP-2. Moreover,the authors provide evidence that the
decreased tyrosine kinase activity of
c-Src in bengamide A treated cells is
molecularly linked to elevated levels
of tyrosine-530 phosphorylation and
decreased levels of tyrosine-419
phosphorylation, but failed to observe
similar regulatory mechanisms in IV-
43 and TNP-470 treated cells, consis-
tent with the fact that c-Src tyrosine ki-
nase activity was not affected in these
cells. The proto-oncogene c-Src is
known to play a pivotal role in cell cy-
cle progression from G2 into mitosis.
Here, the authors show that benga-
mide A induced MetAP inhibition in
HeLa cells resulted in a significant
cell cycle delay, but not cell cycle ar-
rest, at the G2/M phase transition.
These results support a direct link be-
tween MetAP inhibition, deregulation
c-Src, and the observed cell cycle
effects.
Could the myristoylation-targeted
strategy employed so effectively by
Hu and coworkers [1] be copied to be-
come a standard approach to suc-
cessfully investigate the link between
MetAPs and their substrates and
thereby support the analysis of their
cellular functions? While estimates for
N-terminal processing by MetAPs
range from 60%–70% of all cellular
proteins, similar estimates for myris-
toylated proteins place this number
close to 100, thus highlighting a poten-
tially promising direction for future
MetAP research [10]. In the current
report, Hu and colleagues make anChemistry & Biology 14, July 2007 ªimportant contribution to the field by
starting to unlock the ‘‘black box.’’
Beyond fundamental research, this
strategy could have significant impli-
cations for the discovery of novel ther-
apeutic targets. In the clinic, MetAP-2
has a long history as a cancer target
of pharmacological inhibitors of the
fumagillin class, and the therapeutic
promise linked to MetAP-2 inhibition
has now been extended to a broad
array of disease states involving hy-
perproliferative cells and angiogenesis
[11]. Thus, it seems reasonable to envi-
sion that the discovery of novel MetAP
substrates or downstream effectors
in signaling pathways governed by
MetAPs will also translate into the dis-
covery of a new generation of thera-
peutic targets. On a more cautious
note, however, no c-Src inhibitor has
yet found application in the clinic, de-
spite c-Src being one of the most ex-
tensively studied protein kinases with
well-established roles in tumorigene-
sis and metastasis.
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The problem of increasing antibacte-
rial resistance, that modern medicine
faces today, has resulted in quite
a number of studies that deal with nat-
ural antibacterial products and their
biosynthesis. Microcins are defined
as small antibacterial peptides that
are produced by members of the
Enterobacteriaceae. The designation
‘‘microcin’’ was coined to set off the
low molecular weight antibacterial
peptides (<10 kDa) against the large
protein bacteriocins (e.g., the colicins)
that are also produced by these bacte-
ria. All microcins are ribosomally syn-
thesized and they are often posttrans-
lationally modified. Themicrocin group
comprises peptides that differ widely
with respect to their structure and
mode of action. For example, microcin
B17, a peptide that contains thiazole
and oxazole rings, targets the DNA
gyrase, microcin C7, which carries
a C-terminal adenosine monophos-
phate, inhibits protein biosynthesis
[2], and microcin E492 permeabilizes
the cytoplasmic membrane in its
unmodified as well as in its modified
form [3].
Microcin J25 is characterized by
a very unusual and fascinating struc-
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ture: a so-called ‘‘lasso peptide’’ [4].
Lasso peptides are short peptides
(16–21 amino acids) that contain an
N-terminal ring structure that is closed
by an amide bond between the N-ter-
minal amino acid and the side chain
carboxyl group of a glutamic or as-
partic amino acid residue in position
8 or 9. The C-terminal tail is threaded
through this ring structure and forms
a loop or noose, which, in the case of
microcin J25, is stabilized by bulky ar-
omatic residues in the C terminus
(Phe19 and Tyr20) that anchor the
loop above and below the ring (Fig-
ure 1). The resulting backbone struc-
ture resembles a lasso and is very
stable, thus, even after cleavage of
the loop by proteases, the C-terminal
part will stay anchored in the ring [5].
Several other examples of lasso
peptides have been described so far.
Although their modes of action are
very diverse, themajority of these pep-
tides bind to proteins. For example, the
group includes MS-271, an inhibitor of
the calmodulin-activated myosin light
chain kinase [6], anantin, a peptide
binding to the atrial natriuretic factor
(ANF) [7], and two closely related pep-
tides, NP-06 and RP 71955, which are
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nal three-dimensional structure
ere identified and employed to
active against human immunodefi-
ciency virus 1 [8, 9]. The lariatins A
and B [10] and microcin J25 are the
only lasso peptides with antibacterial
activity. Microcin J25 is produced by
and is active against Escherichia coli
strains. Furthermore, it inhibits growth
of someSalmonella serovars. It passes
the outermembrane, taking advantage
of the FhuA iron siderophore trans-
porter [11], and is taken up into the
cytoplasm via other membrane pro-
teins (Smb, TonB, ExbD and ExbB).
Intracellularly it acts as an inhibitor of
the RNA polymerase and stimulates
the production of superoxide [12].
The main producers of lasso pep-
tides characterized so far aremembers
of the actinobacteria and belong to the
genera Streptomyces, Microbiospora,
and Rhodococcus. In order to synthe-
size a lasso peptide, like microcin
J25, the prepeptide has to be folded
in the correct manner, with the N
terminus embracing the C terminus.
Subsequently, the leader peptide
cleavage and the ring formation need
to take place. The enzymes that
catalyze these maturation steps were
unknown until now. For the first
time, Duquesne and coworkers [1]
